Actively Recruiting
Exploring Safety and Effects of S103 CAR-T Cell Therapy for Adults with Progressive or Refractory Multiple Sclerosis
Led by Xijing Hospital · Updated on 2026-08-05
9
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of S103 BCMA-CAR T cells in adults with progressive or refractory multiple sclerosis MS. This exploratory Phase 1 study uses a dose escalation design to explore the safety profile and dose-limiting toxicities of the treatment. The trial enrolls adult patients with progressive or refractory MS who have limited treatment options and aims to recruit a total of 9 patients. Participants will undergo leukapheresis followed by lymphodepletion conditioning with cyclophosphamide and fludarabine. After this, they will receive an infusion of S103 CAR-T cells at varying doses ranging from 0.5 to 2.0 million CAR-T cells per kilogram. The study uses a standard 33 dose escalation design to evaluate increasing doses. The treatment period includes active monitoring for safety and response over several weeks post-infusion. During the study, participants will be closely monitored for side effects and dose-limiting toxicities from Day 1 up to 28 days after infusion, with further safety assessments continuing up to 26 weeks. Researchers will also evaluate biomarkers and disability status changes using the Expanded Disability Status Scale EDSS. Assessments include physical exams, vital signs, lab tests, electrocardiograms, echocardiograms, and multiple biomarker measurements. Participants are followed for approximately six months to assess treatment impact and safety.
CONDITIONS
Brief Title
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Research Team
W
Wen Jiang Dr.
X
Xiaodan Shi Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here